Valbiotis SA (DE:8JD)
FRANKFURT:8JD
8JD Stock Chart & Stats
€0.67
-€0.01(-0.67%)
At close: 4:00 PM EST
€0.67
-€0.01(-0.67%)
Day’s Range― - ―
52-Week Range€0.53 - €1.29
Previous CloseN/A
Volume0.00
Average Volume (3M)407.00
Market Cap
€21.91M
Enterprise Value€23.71M
Total Cash (Recent Filing)€8.68M
Total Debt (Recent Filing)€5.09M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding23,698,235
10 Day Avg. Volume1,223
30 Day Avg. Volume407
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.36
Revenue Forecast (FY)€4.53M
Bulls Say, Bears Say
Bulls Say
Consumer Health Business ModelValbiotis sells consumer-facing nutraceuticals focused on metabolic and cardiovascular prevention. That business model targets large, chronic-demand markets (diabetes, dyslipidemia, hypertension) with recurring purchase potential and diversified channels (retail, pharmacies, e-commerce), supporting durable revenue opportunities.
Scientifically-backed FormulationsProducts positioned as scientifically supported plant-based formulations create differentiation in consumer health. Clinical evidence and scientific positioning can improve credibility with healthcare channels, support premium pricing and partnerships, and raise barriers to entry versus commodity supplements over the medium term.
Moderate Reported LeverageReported debt levels are moderate versus equity, implying the company is not highly levered. This provides some financial flexibility to fund operations or negotiate financing on reasonable terms, which can be valuable while pursuing commercialization and partnership opportunities.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow over multiple years signals the business cannot self-fund growth. Continued cash burn creates ongoing reliance on external capital, raising dilution risk and constraining long-term investment in marketing, R&D, or distribution unless funding sources are secured.
Negative Gross Profit & MarginsNegative gross profit in recent years indicates unit economics currently do not cover direct costs. Persistent negative operating and net margins limit free cash generation and suggest structural issues with pricing, cost base, or scale that must be resolved for durable profitability.
Eroding Equity And Weak ReturnsDeclining equity and assets alongside persistently negative ROE show ongoing value dilution from cumulative losses. This reduces balance-sheet flexibility, weakens the company’s buffer against shocks, and increases the probability that future financing will be expensive or dilutive if profitability is not achieved.
Valbiotis SA News
8JD FAQ
What was Valbiotis SA’s price range in the past 12 months?
Valbiotis SA lowest stock price was €0.53 and its highest was €1.29 in the past 12 months.
What is Valbiotis SA’s market cap?
Valbiotis SA’s market cap is €21.91M.
When is Valbiotis SA’s upcoming earnings report date?
Valbiotis SA’s upcoming earnings report date is Sep 24, 2026 which is in 107 days.
How were Valbiotis SA’s earnings last quarter?
Valbiotis SA released its earnings results on Mar 02, 2026. The company reported -€0.204 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.204.
Is Valbiotis SA overvalued?
According to Wall Street analysts Valbiotis SA’s price is currently Overvalued.
Does Valbiotis SA pay dividends?
Valbiotis SA does not currently pay dividends.
What is Valbiotis SA’s EPS estimate?
Valbiotis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valbiotis SA have?
Valbiotis SA has 23,698,235 shares outstanding.
What happened to Valbiotis SA’s price movement after its last earnings report?
Valbiotis SA reported an EPS of -€0.204 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.309%.
Which hedge fund is a major shareholder of Valbiotis SA?
Currently, no hedge funds are holding shares in DE:8JD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valbiotis SA
Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular diseases. The company's pipeline includes several key candidates: TOTUM-63, currently in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, undergoing Phase II trials to address hypercholesterolemia; and TOTUM-854, which is in Phase II/III clinical development for arterial hypertension. Additionally, Valbiotis is developing TOTUM-448 to treat non-alcoholic fatty liver disease. The company maintains a strategic partnership with Nestlé Health Science.